About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease.

Recent News

March 8, 2021
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

March 3, 2021
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

February 25, 2021
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Events

February 25, 2021
Fourth Quarter and Year End 2020 Financial Results Conference Call

January 19, 2021
NobleCon17: Noble Capital Markets’ Seventeenth Annual Investor / Equity Conference (Virtual)

January 11, 2021
H.C. Wainwright VIRTUAL BioConnect Conference, January 11 – 14, 2021

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

H.C. Wainwright VIRTUAL BioConnect Conference, January 11 – 14, 2021

CD34+ Cell Technology